Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
Open Access
- 20 March 2019
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 57 (1), 8-16
- https://doi.org/10.14412/1995-4484-2019-8-16
Abstract
Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to the population level – are far from solution. This served as a powerful impetus to the study of new approaches to pharmacotherapy of IIRD, one of which is associated with the use of low-molecular synthetic drugs that inhibit intracellular "signal" molecules-Janus kinase (JAK), the socalled Jakinibs. The current achievements and trends concerning the use of JAK inhibitors in the treatment of IIRD are considered.This publication has 98 references indexed in Scilit:
- Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysisAutoimmunity Reviews, 2018
- RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCERheumatology Science and Practice, 2018
- From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implicationsExpert Review of Clinical Immunology, 2018
- Biomarkers in connective tissue diseasesJournal of Allergy and Clinical Immunology, 2017
- Biomarker-guided stratification of autoimmune patients for biologic therapyCurrent Opinion in Immunology, 2017
- Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the LiteratureThe Journal of Rheumatology, 2017
- Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?Annals Of The Rheumatic Diseases, 2017
- Managing rheumatic and musculoskeletal diseases — past, present and futureNature Reviews Rheumatology, 2017
- Treat-to-target as an approach in inflammatory arthritisCurrent Opinion in Rheumatology, 2016
- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challengesNature Reviews Rheumatology, 2015